Aptevo therapeutics announces closing of $8 million offering priced at-the-market under nasdaq rules

Seattle, washington / access newswire / june 20, 2025 / aptevo therapeutics inc. (nasdaq:apvo), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary adaptir™ and adaptir-flex™ platform technologies, today announced the closing of its previously announced offering of (i) 2,465,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 12,325,000 shares of its common stock (the "common warrants") at a purchase price of $3.25 per share and associated common warrants in a registered direct offering priced at-the-market under nasdaq rules. each share of common stock is being offered together with five common warrants, each to purchase one share of common stock.
NDAQ Ratings Summary
NDAQ Quant Ranking